HematologyNews.net

Hematology Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Neurobase.it

Search results for "Velcade"

A phase II study, led by Andre Goy, of the University of Texas M.D. Anderson Cancer Center, Houston, evaluated efficacy and toxicity of Bortezomib ( Velcade ) in 60 patients with relapsed or refractor ...


The FDA ( Food and Drug Administration ) approved a supplemental New Drug Application ( sNDA ) for Velcade ( Bortezomib ). This approval expands the label to include the treatment of patients with m ...


The European Commission has approved the use of Bortezomib ( Velcade ) for Injection as a second-line treatment in patients with multiple myeloma. Bortezomib is indicated as monotherapy for use in ...


A novel strategy devised by Dana-Farber Cancer Institute scientists has proved highly effective in killing drug-resistant multiple myeloma cells in the laboratory. The researchers hope to move rapi ...


Two phase II studies with Bortezomib ( Velcade ) showed very high response rates in front-line multiple myeloma. Overall response rates ranged from 88 to 95 percent with complete and near complete r ...


The results from the phase III APEX study have been published in The New England Journal of Medicine. The study showed Velcade ( Bortezomib ) was superior in survival, time to disease progression, an ...


A new three-drug combination has shown in a phase 1/2 clinical trial that it is a highly effective regimen in the treatment of patients newly diagnosed with multiple myeloma.Partial responses or bette ...


Bruton's tyrosine kinase ( BTK ) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, Ibrutinib ( Imbruvica ), a BTK inhibitor, ...


The results from PANORAMA-1 ( PANobinostat ORAl in Multiple MyelomA ) trial were presented at ASCO meeting, showing a 37% improvement in progression-free survival ( PFS ) when using the investigationa ...


In 2013 American Society of Hematology ( ASH ) Annual Meeting data on several compounds in development for the treatment of multiple myeloma were presented. Alternating vs sequential regimens I ...


VMP and Rd are two of the most efficient and widely accepted regimens in the treatment of elderly newly diagnosed multiple myeloma patients. In order to further improve the outcome of elderly patients ...


The FDA ( Food and Drug Administration ) has approved Farydak ( Panobinostat, previously known as LBH589 ) capsules in combination with Bortezomib ( Velcade ) and Dexamethasone for the treatment of pa ...


A planned interim analysis has shown that the phase 3 head-to-head clinical trial ENDEAVOR evaluating Carfilzomib ( Kyprolis ) for injection in combination with low-dose Dexamethasone versus Bortezomi ...


Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were presented. The study met the key secondary endpoint of overall survival, demons ...